Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 8/20 | 0.48 |
| ▸ | PDE1A | P54750 | 6/20 | 0.48 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.48 |
| ▸ | PDE2A | O00408 | 5/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PARG | Q86W56 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9608323 | 0.93 | PDE1B (0.47) | PDE1BPDE1APDE1CPDE2APDE4D | |
| SCHEMBL9608334 | 0.89 | PDE1B (0.52) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL2461370 | 0.86 | PDE1A (0.49) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL9608337 | 0.85 | PDE1B (0.48) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL2455942 | 0.85 | PDE1B (0.48) | PDE1BPDE1APDE1CPDE2APDE4A | |
| SCHEMBL9608307 | 0.85 | PDE1B (0.48) | PDE1BPDE1APDE1CPDE2APDE4A | |
| SCHEMBL2454720 | 0.85 | PDE1B (0.50) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL16369452 | 0.84 | PDE1B (0.52) | PDE1BPDE1APDE1CPDE2ASLC16A1 | |
| SCHEMBL2462950 | 0.82 | PDE1B (0.50) | PDE1BPDE1APDE1CPDE2APDE4A | |
| SCHEMBL2454858 | 0.82 | PDE1A (0.48) | PDE1BPDE1APDE1CPDE2ASLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136013-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES. INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2010065147-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136013-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | PDE1B 4855/4885PDE1A 4874/4885PDE1C 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.